1. During a season in which a substantial fraction of circulating influenza A carries the H275Y neuraminidase substitution, a clinician reasons about which oral agent will remain reliably effective. Integrating the molecular target of each drug with the location of the resistance mutation, which conclusion is best supported?
A) Baloxavir should retain activity because it inhibits the polymerase acidic subunit endonuclease, a target distinct from neuraminidase, so a neuraminidase-site mutation does not reduce its binding
B) Oseltamivir should retain activity because H275Y reduces binding only modestly and can be overcome by standard dosing
C) Amantadine should retain activity because adamantane and neuraminidase resistance never coexist in the same strain
D) All oral agents should fail because H275Y alters a binding pocket shared across the antiviral classes
E) Zanamivir should fail in parallel with oseltamivir because the two drugs bind the neuraminidase site identically
ANSWER: A
Rationale:
H275Y is a neuraminidase-site mutation. Baloxavir acts at a different protein altogether — the cap-dependent endonuclease of the polymerase acidic subunit — so a mutation in neuraminidase does not reduce baloxavir binding, and baloxavir reliably retains activity.
Option B: Option B is incorrect: H275Y confers high-level, not modest, oseltamivir resistance and is not reliably overcome by dose escalation.
Option C: Option C is incorrect: adamantanes are clinically obsolete for influenza A because of near-universal M2 resistance, so amantadine is not a reliable choice regardless of neuraminidase status.
Option D: Option D is incorrect: there is no shared binding pocket across these classes; each drug class binds a distinct target.
Option E: Option E is incorrect: zanamivir contacts the neuraminidase active site differently from oseltamivir and characteristically retains activity against H275Y, so it does not fail in parallel.
2. A hospitalized patient with severe chronic obstructive pulmonary disease and influenza is intubated and receiving enteral feeds that are frequently interrupted, making reliable oral absorption uncertain; inhaled delivery is also problematic. Integrating route of administration with this patient's airway disease and absorption reliability, which neuraminidase inhibitor is the most appropriate choice?
A) Inhaled zanamivir, because it delivers drug directly to the infected airway
B) Oral oseltamivir, because enteral absorption is unaffected by feed interruptions
C) Intravenous peramivir, because it bypasses both the unreliable enteral route and the bronchospasm risk that inhaled zanamivir poses in obstructive airway disease
D) Oral baloxavir, because a single dose removes any concern about route
E) No neuraminidase inhibitor, because all are contraindicated in chronic obstructive pulmonary disease
ANSWER: C
Rationale:
Intravenous peramivir bypasses the unreliable enteral route and avoids the bronchospasm risk that inhaled zanamivir carries in obstructive airway disease, making it the best fit when both oral absorption and inhalation are problematic.
Option A: Option A is incorrect: inhaled zanamivir can provoke bronchospasm in obstructive airway disease and is therefore a poor choice here.
Option B: Option B is incorrect: the scenario specifies that enteral absorption is unreliable because of frequent feed interruptions, undercutting dependence on oral oseltamivir.
Option D: Option D is incorrect: baloxavir is also oral, so it shares the unreliable-absorption problem; route is precisely the issue.
Option E: Option E is incorrect: neuraminidase inhibitors are not contraindicated in chronic obstructive pulmonary disease as a class — only the inhaled route is problematic — so withholding all of them is wrong.
3. A trainee asks why baloxavir can be given as a single dose yet still selects for treatment-emergent resistance in some patients. Integrating its pharmacokinetics with its mechanism, which explanation is best?
A) Its short half-life requires frequent dosing, and resistance reflects missed doses
B) It permanently inactivates the polymerase, so resistance cannot emerge during a single course
C) Resistance reflects pre-existing neuraminidase mutations unrelated to baloxavir exposure
D) Its single-dose schedule guarantees subtherapeutic levels, which is why resistance is universal
E) Its long active-acid half-life sustains drug pressure across the replication window from one dose, and because it acts at a single polymerase target, position-38 substitutions in the polymerase acidic subunit can be selected during that exposure
ANSWER: E
Rationale:
Baloxavir acid has a long half-life that sustains effective concentrations from a single dose across the period of active replication; because the drug acts at one polymerase target, a single substitution at position 38 of the polymerase acidic subunit can reduce binding and be selected under that sustained pressure, producing treatment-emergent resistance in a minority of patients.
Option A: Option A is incorrect: baloxavir's half-life is long, not short, and single-dose therapy is intentional rather than a consequence of missed doses.
Option B: Option B is incorrect: baloxavir reversibly inhibits the endonuclease and does not permanently inactivate the polymerase, so resistance can emerge.
Option C: Option C is incorrect: baloxavir resistance involves polymerase position-38 substitutions, not pre-existing neuraminidase mutations.
Option D: Option D is incorrect: the single dose produces sustained therapeutic, not subtherapeutic, levels, and treatment-emergent resistance is a minority event rather than universal.
4. A kidney transplant recipient maintained on tacrolimus develops mild COVID-19 and is being considered for nirmatrelvir-ritonavir. Integrating ritonavir's pharmacologic role with tacrolimus metabolism, what is the predicted interaction and the most appropriate response?
A) Tacrolimus levels will fall because ritonavir induces its metabolism, so the tacrolimus dose should be increased empirically
B) Tacrolimus levels will rise sharply because ritonavir inhibits the CYP3A4 enzyme that clears tacrolimus, risking nephrotoxicity and neurotoxicity, so the interaction must be managed with dose modification and close monitoring or an alternative antiviral chosen
C) There will be no interaction because ritonavir affects only nirmatrelvir concentrations
D) Nirmatrelvir will be rendered ineffective because tacrolimus competes for the main protease
E) Ritonavir will accelerate tacrolimus clearance, requiring a higher tacrolimus dose during therapy
ANSWER: B
Rationale:
Ritonavir is a potent CYP3A4 inhibitor, and tacrolimus is heavily CYP3A4-dependent for clearance; coadministration can raise tacrolimus concentrations sharply, risking nephrotoxicity and neurotoxicity, so the interaction requires careful dose modification with close monitoring or selection of an alternative antiviral.
Option A: Option A is incorrect: ritonavir inhibits rather than induces CYP3A4, so tacrolimus levels rise, not fall, and empiric dose increase would be dangerous.
Option C: Option C is incorrect: ritonavir's CYP3A4 inhibition affects any CYP3A4 substrate, not only nirmatrelvir, which is the basis of this drug's extensive interactions.
Option D: Option D is incorrect: tacrolimus does not compete at the viral main protease, and the concern is elevated tacrolimus levels rather than antiviral failure.
Option E: Option E is incorrect: ritonavir slows, not accelerates, tacrolimus clearance, so a higher tacrolimus dose is the opposite of what is needed.
5. A surveillance team compares two resistance substitutions: the adamantane M2 substitution S31N and the baloxavir polymerase substitution PA-I38T. Integrating the concept of fitness cost with observed epidemiology, which prediction is best supported?
A) Both will spread to near-universal prevalence because any resistance mutation eventually dominates
B) Neither will spread because resistance mutations are always eliminated between seasons
C) PA-I38T will spread more widely than S31N because polymerase mutations are inherently more transmissible
D) S31N is expected to spread widely because it imposes minimal fitness cost, whereas PA-I38T is expected to spread less efficiently because it imposes a greater fitness cost that constrains transmission
E) Spread cannot be predicted from fitness cost because transmission depends only on drug-prescribing volume
ANSWER: D
Rationale:
The likelihood that a resistance mutation spreads is governed chiefly by its fitness cost. S31N disrupts adamantane binding while barely affecting M2 function — a low fitness cost — and has indeed spread to near-universal prevalence; PA-I38T imposes a greater fitness cost, which constrains its transmission, consistent with its more limited community spread.
Option A: Option A is incorrect: not every resistance mutation dominates; high-fitness-cost mutations spread poorly.
Option B: Option B is incorrect: low-cost mutations such as S31N persist and spread rather than being reliably eliminated between seasons.
Option C: Option C is incorrect: polymerase mutations are not inherently more transmissible; PA-I38T in fact carries a higher fitness cost and spreads less than S31N.
Option E: Option E is incorrect: fitness cost, not prescribing volume alone, is the central determinant of whether resistance spreads.
6. A neonatology group reviews why nirsevimab achieves season-long respiratory syncytial virus protection from one injection and is a more potent neutralizer than older antibodies. Integrating the antibody's epitope target with its molecular engineering, which explanation is best?
A) It binds a prefusion-specific epitope of the fusion protein — a conformation that elicits substantially more potent neutralization than the postfusion form — and carries an engineered extended-half-life Fc region that sustains protective levels across an entire season from a single dose
B) It binds the postfusion conformation of the fusion protein, which is the most potent neutralizing target, and is dosed monthly like palivizumab
C) It targets the attachment glycoprotein and provides active immunity that matures over the season
D) It inhibits the viral polymerase, which is why a single dose suffices
E) It is a small-molecule fusion inhibitor whose long tissue retention explains single dosing
ANSWER: A
Rationale:
Antibodies to the prefusion conformation of the fusion protein neutralize far more potently than those targeting the postfusion form; nirsevimab binds a prefusion-specific epitope and is engineered with an extended-half-life Fc region, so a single dose maintains protective concentrations across the season.
Option B: Option B is incorrect: prefusion, not postfusion, binding is the more potent neutralizing strategy, and nirsevimab is dosed once rather than monthly.
Option C: Option C is incorrect: nirsevimab targets the fusion protein and provides passive immunity, not active immunity that matures over time.
Option D: Option D is incorrect: it is a monoclonal antibody against the fusion protein, not a polymerase inhibitor.
Option E: Option E is incorrect: nirsevimab is a monoclonal antibody, not a small molecule, and its single dosing reflects Fc engineering rather than tissue retention of a small molecule.
7. A transplant team weighs aerosolized ribavirin for a hematopoietic stem cell transplant recipient with severe respiratory syncytial virus lower respiratory tract disease. Integrating the strength of evidence, the drug's hazards, and the patient population, which statement best frames its appropriate use?
A) Ribavirin is first-line for all respiratory syncytial virus infections because randomized trials show strong benefit in immunocompetent infants
B) Ribavirin should be avoided entirely because it has no plausible antiviral mechanism against respiratory syncytial virus
C) Evidence of benefit in routine infant bronchiolitis is weak, so use is reserved for selected severely ill immunocompromised patients such as transplant recipients, where observational data suggest possible benefit, while accounting for its teratogenicity and the need for staff respiratory protection during aerosol administration
D) Ribavirin is preferred over monoclonal antibodies for routine prophylaxis because it is inhaled
E) Ribavirin is contraindicated in transplant recipients because immunosuppression abolishes its activity
ANSWER: C
Rationale:
Randomized evidence for aerosolized ribavirin in routine infant bronchiolitis is weak, so its use has narrowed to selected severely ill immunocompromised patients such as hematopoietic stem cell transplant recipients, where observational data suggest possible benefit; this reserved use must be weighed against the drug's teratogenicity and the requirement for staff respiratory protection during aerosol administration.
Option A: Option A is incorrect: ribavirin is not first-line for all respiratory syncytial virus infection, and trial evidence in immunocompetent infants is weak rather than strong.
Option B: Option B is incorrect: ribavirin does have plausible antiviral mechanisms (inosine monophosphate dehydrogenase inhibition, direct polymerase inhibition, and lethal mutagenesis), so avoiding it as mechanism-less is wrong.
Option D: Option D is incorrect: routine respiratory syncytial virus prophylaxis uses monoclonal antibodies (nirsevimab, palivizumab), not aerosolized ribavirin.
Option E: Option E is incorrect: ribavirin is not contraindicated in transplant recipients; that population is in fact where its reserved use is concentrated.
8. Investigators studying severe influenza propose combining baloxavir with oseltamivir. Integrating the mechanisms of the two agents, what is the most coherent rationale for such a combination?
A) The two drugs share a target, so combining them simply doubles inhibition at that single site
B) Oseltamivir activates baloxavir, so the combination is required for baloxavir to work at all
C) Baloxavir blocks neuraminidase while oseltamivir blocks the polymerase, providing redundant coverage of the same enzyme
D) The combination is irrational because the two drugs antagonize each other at a common binding pocket
E) The drugs act at two distinct replication steps — baloxavir inhibits the polymerase acidic subunit endonuclease while oseltamivir inhibits neuraminidase-mediated virion release — so attacking two targets may enhance viral suppression and reduce the chance that a single resistance substitution defeats therapy
ANSWER: E
Rationale:
Baloxavir inhibits the polymerase acidic subunit endonuclease (an early transcription step) while oseltamivir inhibits neuraminidase-mediated virion release (a late step); attacking two distinct steps can enhance suppression and makes it less likely that a single resistance substitution will defeat both drugs, which is the rationale for investigating the combination in severe influenza.
Option A: Option A is incorrect: the two drugs do not share a target, so the premise of doubling inhibition at one site is wrong.
Option B: Option B is incorrect: oseltamivir does not activate baloxavir; baloxavir is activated by arylacetamide deacetylase independently.
Option C: Option C is incorrect: it reverses the mechanisms — baloxavir targets the polymerase and oseltamivir targets neuraminidase, and the coverage is complementary, not redundant.
Option D: Option D is incorrect: the drugs act at different targets and do not share a binding pocket, so mutual antagonism is not the expected interaction.
9. Midway through a season, a drifted influenza A strain is circulating that the current vaccine matches poorly, and vaccinated high-risk patients are presenting with influenza. Integrating the concept of antigenic change with antiviral mechanism, what is the most sound clinical inference?
A) Antivirals will also fail against the drifted strain because antigenic drift alters drug-binding sites along with antigenic sites
B) Antivirals such as neuraminidase inhibitors and baloxavir remain useful because they target conserved viral enzymes rather than the variable surface antigens that vaccine immunity and antigenic drift concern
C) The drifted strain cannot be treated at all and management is purely supportive
D) Vaccinating again immediately with the same vaccine will provide rapid protection against the drifted strain
E) Only adamantanes will work, because antigenic drift does not affect the M2 channel
ANSWER: B
Rationale:
Antigenic drift alters the variable surface glycoproteins that determine vaccine match, but neuraminidase inhibitors and baloxavir act on conserved viral enzymes (the neuraminidase catalytic site and the polymerase endonuclease), so they remain useful even when vaccine-induced immunity is evaded by a drifted strain.
Option A: Option A is incorrect: drift changes antigenic sites, not the conserved enzymatic drug targets, so it does not automatically confer drug resistance.
Option C: Option C is incorrect: a vaccine-mismatched strain is still treatable with antivirals, so management is not limited to supportive care.
Option D: Option D is incorrect: repeat dosing of a poorly matched vaccine does not rapidly generate protection against the drifted strain.
Option E: Option E is incorrect: adamantanes are clinically obsolete because of near-universal M2 resistance, so they are not the agents that remain effective.
10. A hospital team debates which COVID-19 inpatients are most likely to benefit from remdesivir. Integrating the drug's antiviral mechanism with the natural history of severe COVID-19, which patients are expected to derive the greatest benefit, and why?
A) Patients on prolonged mechanical ventilation, because that is when viral replication peaks and an antiviral has the most to suppress
B) Patients without hypoxemia who are about to be discharged, because antiviral effect is unrelated to disease stage
C) Patients in the late hyperinflammatory phase, because remdesivir's primary action is anti-inflammatory
D) Patients requiring low-flow supplemental oxygen who have not yet progressed to mechanical ventilation, because remdesivir suppresses viral replication and is most useful earlier in the disease course while replication still drives pathology, with less clear benefit once severe inflammation predominates
E) No hospitalized patients, because remdesivir is approved only for outpatients
ANSWER: D
Rationale:
Remdesivir suppresses viral replication, so its benefit concentrates earlier in the disease course while replication is still driving pathology; the clearest measurable inpatient benefit is in patients requiring low-flow supplemental oxygen who have not yet progressed to mechanical ventilation, with less clear benefit once severe inflammation predominates.
Option A: Option A is incorrect: by the time patients require prolonged mechanical ventilation, inflammation rather than ongoing replication tends to drive disease, and antiviral benefit is less clear.
Option B: Option B is incorrect: antiviral benefit is stage-dependent, not stage-independent, so this premise is wrong.
Option C: Option C is incorrect: remdesivir is an antiviral acting on the polymerase, not an anti-inflammatory agent.
Option E: Option E is incorrect: remdesivir is approved for hospitalized patients (and also has a high-risk outpatient course), so restricting it to outpatients only is incorrect.
11. Two patients present on day 3 of influenza: a healthy 25-year-old outpatient and a 70-year-old with chronic lung disease and worsening dyspnea. Integrating viral replication kinetics with host risk, how should antiviral decisions differ between them?
A) Treat the high-risk older patient because benefit persists beyond 48 hours in high-risk and progressing illness, while recognizing that the healthy outpatient at the same time point derives diminishing benefit as replication wanes
B) Treat the healthy outpatient but not the high-risk patient, because antivirals are unsafe in the elderly
C) Treat neither, because day 3 is uniformly beyond the window in which antivirals provide any benefit
D) Treat both identically because time from symptom onset is the only factor that matters
E) Defer treatment in both until the replication peak passes to avoid selecting resistance
ANSWER: A
Rationale:
Replication wanes after roughly 48 to 72 hours, so a healthy outpatient presenting on day 3 derives diminishing benefit; however, benefit persists beyond 48 hours in high-risk patients and those with severe or progressing illness, so the older patient with worsening dyspnea should be treated. Integrating kinetics with host risk yields different decisions for the two patients.
Option B: Option B is incorrect: antivirals are not unsafe in the elderly, and the high-risk patient is precisely the one who should be treated.
Option C: Option C is incorrect: benefit is not uniformly absent at day 3 — it persists in high-risk and progressing illness.
Option D: Option D is incorrect: host risk and disease trajectory, not time from onset alone, drive the decision.
Option E: Option E is incorrect: deferring treatment to await the replication peak is contrary to the principle of suppressing active replication promptly, especially in a deteriorating high-risk patient.
12. A learner proposes that an M2 ion-channel blocker could be repurposed to treat influenza B if resistance in influenza A is the only problem. Integrating the structural basis of adamantane action with influenza B biology, why is this reasoning flawed?
A) Influenza B replicates in the cytoplasm and has no uncoating step, so no drug can act on entry
B) Influenza B lacks neuraminidase, so any ion-channel drug would be redundant
C) Influenza B does not possess the M2 channel; it uses a structurally distinct ion channel (BM2) whose pore architecture adamantanes do not block, so an M2 blocker has no target in influenza B regardless of the resistance situation in influenza A
D) Influenza B carries the S31N substitution constitutively, so adamantanes are pre-empted by resistance rather than by target absence
E) Adamantanes would work against influenza B, but only at doses that are universally neurotoxic
ANSWER: C
Rationale:
Adamantanes act by physically obstructing the influenza A M2 proton channel. Influenza B does not have M2; it uses a structurally distinct channel, BM2, whose pore the adamantanes do not block, so an M2 blocker simply has no target in influenza B — independent of any resistance issue in influenza A.
Option A: Option A is incorrect: influenza B does undergo an uncoating step; the issue is the absence of the M2 target, not the absence of uncoating.
Option B: Option B is incorrect: influenza B does possess neuraminidase (which is why neuraminidase inhibitors work against it), and the adamantane problem concerns the ion channel, not neuraminidase redundancy.
Option D: Option D is incorrect: S31N is an acquired influenza A M2 mutation, not a constitutive feature of influenza B, which lacks M2 altogether.
Option E: Option E is incorrect: the barrier is target absence, not a dose-toxicity tradeoff.
13. A pregnant patient develops influenza, and local surveillance shows the circulating strain carries oseltamivir-conferring H275Y resistance. She can take oral or inhaled medication. Integrating the resistance pattern, the pregnancy consideration, and route options, which choice is most defensible?
A) Standard-dose oral oseltamivir, because pregnancy outweighs the resistance concern
B) Amantadine, because adamantane resistance and neuraminidase resistance never coexist
C) Aerosolized ribavirin, because it is the safest option in pregnancy
D) Baloxavir, because it is the preferred influenza antiviral in pregnancy
E) Inhaled zanamivir, because H275Y characteristically preserves zanamivir susceptibility and zanamivir, like oseltamivir, has a more established safety record in pregnancy than baloxavir, which has limited pregnancy data
ANSWER: E
Rationale:
H275Y characteristically spares zanamivir, so it remains active against this strain, and the neuraminidase inhibitors have a more established safety record in pregnancy than baloxavir, for which pregnancy data are limited; with both oral and inhaled routes available, inhaled zanamivir is a defensible choice here.
Option A: Option A is incorrect: H275Y confers high-level oseltamivir resistance, so standard-dose oseltamivir is unlikely to be effective against this strain.
Option B: Option B is incorrect: adamantanes are clinically obsolete because of near-universal M2 resistance, and the claim that the two resistance types never coexist is false.
Option C: Option C is incorrect: ribavirin is teratogenic and is not an appropriate influenza treatment, let alone the safest option in pregnancy.
Option D: Option D is incorrect: baloxavir is not the preferred agent in pregnancy because of limited data, so it is not the most defensible choice when a neuraminidase inhibitor that the strain remains susceptible to is available.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.